<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01905150</url>
  </required_header>
  <id_info>
    <org_study_id>119005</org_study_id>
    <nct_id>NCT01905150</nct_id>
  </id_info>
  <brief_title>Ph 2 Trial of Vitamin C &amp; G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer</brief_title>
  <official_title>Ph 2 Trial of G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan &amp; Oxaliplatin), Followed by G-FLIP-DM (G-FLIP + Low Doses Docetaxel &amp; MitomycinC), When Used in Combination With Vitamin C, in Patients With Advanced Pancreatic Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bruckner Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bruckner Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic cancer, especially at advanced metastatic stage, is a devastating disease. It is
      the fourth leading cause of cancer death. Its prognosis is grim - 5-year survival rate being
      6%. The current therapies for advanced metastatic pancreatic cancer are very toxic and with
      limited efficacy. A safer and more effective therapy for this devastating disease is greatly
      needed.

      G-FLIP regimen is a combination of low doses (doses lower than those approved by the FDA and
      used in the clinic) of several anti-cancer drugs, Gemcitabine, Fluorouracil, Leucovorin,
      Irinotecan and Oxaliplatin. The efficacy of G-FLIP against cancers (especially pancreatic
      cancer) is based on laboratory and clinical results, which indicates the synergistic efficacy
      of these anti-cancer drugs against cancer cells and overcoming tumor drug resistance that
      cancer cells frequently develop. Also, because of their low doses, this regimen is less toxic
      than when these drugs are used alone.

      Meanwhile, intravenous infusion of high doses (doses significantly higher than the daily
      nutritional requirements) of Vitamin C (ascorbic acid) has been observed to have anti-cancer
      activities. This is especially true when Vitamin C is used in combination with other
      anti-cancer drugs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY OBJECTIVE

      The objective of this study is to evaluate the safety, tolerability and efficacy of G-FLIP
      (Low Doses of Gemcitabine, Fluorouracil [5FU], Leucovorin, Irinotecan, and Oxaliplatin), when
      used in combination with ascorbic acid (Vitamin C), as first-line therapy in patients with
      advanced pancreatic cancer. The objective of this study is also to evaluate the safety,
      tolerability and efficacy of G-FLIP-DM (G-FLIP + Low Doses of Docetaxel and Mitomycin C),
      when used in combination with ascorbic acid, in patients with advanced pancreatic cancer who
      develop Disease Progression (DP) with G-FLIP treatment. The primary endpoint is 12-month
      survival rate. The secondary endpoints include Overall Survival (OS), Quality of Life (QOL),
      Response Rate (RR), Progression-Free-Survival (PFS), and safety.

      STUDY DRUGS

      Study drugs include G-FLIP, G-FLIP-DM, and Vitamin C (Ascorbic Acid)

      STUDY DESIGN

      Sample Size:

      There will be 30 &quot;evaluable&quot; study subjects in this study.

      Treatments:

      G-FLIP: All study subjects are treated with G-FLIP. Each treatment cycle of G-FLIP is 2
      weeks, with G-FLIP given on Days 1 and 2 of each cycle. If study subjects exhibit Disease
      Progression (DP), treatment with G-FLIP will stop, and they will be treated with G-FLIP-DM.

      G-FLIP-DM: Study subjects who exhibit DP with G-FLIP treatment will be treated with
      G-FLIP-DM. Each G-FLIP-DM treatment cycle is 2 weeks, with G-FLIP-DM given on Days 1 and 2 of
      each cycle.

      Ascorbic Acid: Ascorbic acid will be administered twice weekly throughout the study, given on
      any 2 separate days of the week. Ascorbic acid will be administered throughout the study
      including during the follow-up period, even if treatment with G-FLIP or G-FLIP-DM has been
      terminated due to DP. Additionally, in 50% of the study subjects (i.e., 15 evaluable study
      subjects), treatment with ascorbic acid will begin on the same week when G-FLIP begins. In
      the other 50% of the study subjects (i.e., the other 15 evaluable study subjects), treatment
      with ascorbic acid will be delayed by 2 cycles. Results from these 2 groups of study subjects
      would allow comparison of potential acute safety of ascorbic acid, when used in combination
      with G-FLIP.

      Open-Label: This is an open-label study, where investigators and study subjects are not
      blinded to the treatment.

      Randomization: The assignment of study subjects will be randomized, as long as they meet
      eligibility criteria of the study.

      DOSE DELAY AND DOSE MODIFICATION

      In the event of adverse drug reactions, dose delay and dose modification will be dependent on
      the type of toxicities. The detailed dose modification scheme for G-FLIP, G-FLIP-DM and
      Ascorbic Acid are outlined in the protocol.

      CONCOMITANT MEDICATIONS AND PROPHYLACTIC TREATMENT

      Other than G-FLIP, G-FLIP-DM and ascorbic acid, patients cannot receive any other standard or
      investigational treatment for their cancer, or any study drugs for any non-cancer
      indications, while on this study. All concomitant medications (including names, dosage and
      schedule) must be recorded.

      Prophylactic treatment for drug-related symptoms can be given according to Package Inserts of
      the study drugs and clinical practice. Supportive treatment may include anti-emetic,
      anti-diarrhea, anti-pyretic, anti-allergic, anti-hypertensive, analgesics, antibiotics,
      allopurinol, and others such as blood products and bone marrow growth factors. Patients may
      use erythropoietin for anemia. The investigator may utilize erythropoietic factors, or blood
      or platelet transfusions at their discretion.

      DURATION OF TREATMENT AND FOLLOW-UP

      At least six months of treatment is recommended for study subjects who have a response from
      G-FLIP or G-FLIP-DM, unless or until:

        -  Patients exhibit disease progression in the opinion of the principal investigator

        -  Unacceptable toxicity from the treatment

        -  Patient withdrawal of consent (Note: The investigator should make every effort to
           contact the subject to perform a final evaluation and to determine the reason(s) for
           withdrawal from the study.)

        -  Investigator's discretion to withdraw patients from the study because continued
           participation in the study is not in the patient's best interest.

        -  Underlying illness: a condition, injury, or disease unrelated to the intended disease
           which the study is investigating, that renders continuing treatment unsafe or regular
           follow-up impossible

        -  General or specific changes in the patient's condition that renders the patient
           ineligible for further investigational treatment

        -  Non-compliance with investigational treatment, protocol-required evaluations or
           follow-up visits

      After treatment, study subjects should be followed so that information on survival and post
      study treatment are available for at least 1 year after the study subjects participate in the
      trial.

      EFFICACY ASSESSMENTS

      The efficacy of the study drugs will be assessed according to the following parameters:

      Response Criteria of Complete Response (CR), Partial Response (PR), Stable Disease (SD), and
      Progressive Disease (Disease Progression or DP) will be derived from CT or MRI according to
      Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Eisenhauer et al. 2009).

      Response Rate (RR) is the number of study subjects, expressed as a percentage of the total
      number of study subjects participated in the trial, who exhibit PR or CR that has been
      confirmed from 2 consecutive scans (CT or MRI).

      Progression-Free-Survival (PFS) is the length of time when SD (or better) of a study subject
      is first documented until the time when DP, or death from any cause, occurs.

      Overall Survival (OStreatment) is the time from which the study subjects are first treated
      with G-FLIP to the time when death from any cause occurs. OS, which is the time from which
      the study subjects are first diagnosed with advanced pancreatic cancer to the time when death
      from any cause occurs, will also be recorded.

      12-Month Survival Rate is the number of study subjects, expressed as a percentage of the
      total number of study subjects in the trial, who survive for 12 months starting from the time
      when the study subjects are accrued to the trial. The 12-Month Survival Rate for study
      subjects who survive for 12 months starting from the time when the study subjects are first
      diagnosed with advanced pancreatic cancer will also be recorded.

      Safety Assessments

      The efficacy of the study drugs will be assessed from the first dose to 1 month after last
      dose of the study drugs. The assessments will be based on the following parameters, performed
      at baselines and at various times during the study:

        -  physical exams

        -  evaluation of symptoms

        -  vital signs

        -  ECOG performance status and survival

        -  clinical pathology (clinical chemistry, renal function [assessed utilizing the
           Cockcroft-Gault formula], hematology, and coagulation)

        -  urinalysis

        -  QOL, assessed as described by Aaronson NK, et al. 1993.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12-month survival rate</measure>
    <time_frame>12 months</time_frame>
    <description>The number of subjects that survive 12 months after the start of treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>2 years</time_frame>
    <description>The number of study subjects survive for 2 years since the start of treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quality of Life</measure>
    <time_frame>1 year</time_frame>
    <description>The Quality of Life for a year since the start of treatment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Response Rate (RR)</measure>
    <time_frame>1 year</time_frame>
    <description>The number of study subjects that have a Partial Response (PR) or Complete Response (CR).</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression-Free-Survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>The duration of Stable Disease (SD), Partial Response (PR), or Complete Response (CR)</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>1 year</time_frame>
    <description>The incidence of adverse events, as measured by blood tests, signs/symptoms, etc.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>G-FLIP+VitaminC, then G-FLIP-DM+VitaminC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G-FLIP in combination with Vitamin C, then G-FLIP-DM in combination with Vitamin C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G-FLIP, then G-FLIP-DM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>G-FLIP alone, then G-GLIP-DM alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-FLIP</intervention_name>
    <description>G-FLIP is a combination of Low Doses of Gemcitabine, Fluorouracil [5FU], Leucovorin, Irinotecan, and Oxaliplatin</description>
    <arm_group_label>G-FLIP+VitaminC, then G-FLIP-DM+VitaminC</arm_group_label>
    <arm_group_label>G-FLIP, then G-FLIP-DM</arm_group_label>
    <other_name>Low doses of Gemcitabine</other_name>
    <other_name>Low dose Fluorouracil [5FU]</other_name>
    <other_name>Leucovorin</other_name>
    <other_name>Low dose Irinotecan</other_name>
    <other_name>Low dose Oxaliplatin)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G-FLIP-DM</intervention_name>
    <description>G-FLIP-DM is low doses of Gemcitabine, Fluorouracil [5FU], Leucovorin, Irinotecan, Oxaliplatin, Docetaxel and Mitomycin C</description>
    <arm_group_label>G-FLIP+VitaminC, then G-FLIP-DM+VitaminC</arm_group_label>
    <arm_group_label>G-FLIP, then G-FLIP-DM</arm_group_label>
    <other_name>Low dose Gemcitabine</other_name>
    <other_name>Low dose Fluorouracil or 5FU</other_name>
    <other_name>Leucovorin</other_name>
    <other_name>Low dose Irinotecan</other_name>
    <other_name>Low dose Oxaliplatin</other_name>
    <other_name>Low dose Docetaxel</other_name>
    <other_name>Low dose Mitomycin C</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin C</intervention_name>
    <description>High dose of Vitamin C, used in combination with G-FLIP and then G-FLIP-DM</description>
    <arm_group_label>G-FLIP+VitaminC, then G-FLIP-DM+VitaminC</arm_group_label>
    <other_name>Ascorbic Acid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have histologically and cytologically confirmed metastatic (Stage IV),
             locally advanced unresectable (stage III), or locally recurrent pancreatic
             adenocarcinoma, with or without prior chemotherapy for their cancer.

          -  Eastern Cooperative Oncology Group (ECOG) performance status being 0-2.

          -  Expected survival &gt;3 months.

          -  Patients 18 years of age and older of both genders.

          -  Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically
             sterile) must use accepted contraceptive methods (abstinence, intrauterine device
             [IUD], oral contraceptive or double barrier device) during the study, and must have a
             negative serum or urine pregnancy test within 2 weeks prior to treatment initiation.

          -  Fertile men must practice effective contraceptive methods during the study, unless
             documentation of infertility exists.

          -  At least 2 weeks must have elapsed from any prior surgery or hormonal therapy.

          -  Laboratory values â‰¤2 weeks must be:

               -  Adequate hematologic

               -  Adequate hepatic function

               -  Adequate renal function

          -  No evidence of active infection and no serious infections within the past month.

          -  Mentally competent, able to understand and willing to sign the informed consent form.

        Exclusion Criteria:

          -  Patients under the age of 18.

          -  Locally advanced resectable disease from pancreatic cancer

          -  Previous radiotherapy for cerebral metastases, central nervous system (CNS) or
             epidural tumor.

          -  Patients receiving any other standard or investigational treatment for their cancer,
             or any other investigational agent for any non-cancer indication within the past 4
             weeks.

          -  Patients with any active uncontrolled bleeding, or a bleeding diathesis.

          -  Pregnant women, or women of child-bearing potential not using reliable means of
             contraception.

          -  Lactating females.

          -  Fertile men unwilling to practice contraceptive methods during the study period.

          -  Life expectancy less than 3 months.

          -  Any condition or abnormality which may, in the opinion of the investigator, compromise
             the safety of patients.

          -  Unwilling or unable to follow protocol requirements.

          -  Active heart disease including but not limited to symptomatic congestive heart
             failure, symptomatic coronary artery disease, symptomatic angina pectoris, symptomatic
             myocardial infarction, or symptomatic congestive heart failure.

          -  Patients with a history of myocardial infarction that is &lt; 3 months prior to
             registration.

          -  Patients with any amount of clinically significant pericardial effusion.

          -  Evidence of active serious infection.

          -  Patients with known HIV infection.

          -  Requirement for immediate palliative treatment of any kind including surgery and
             radiation.

          -  Patients that have received a chemotherapy regimen requiring stem cell support in the
             previous 6 months.

          -  Any condition or abnormality which may, in the opinion of the investigator, compromise
             the safety of the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Azriel Hirschfeld, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bruckner Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bruckner Oncology</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10469</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bruckner H, Hirschfeld A, Buddaraju S, Stega J, Jahan M, Schwartz ME. Multidisciplinary effect of adding docetaxel and mitomycin-C to low-dose multidrug therapy for cholangiocarcinoma. J Clin Oncol 29: 2011 (suppl; abstr e14546)</citation>
  </reference>
  <reference>
    <citation>Bruckner HW, Myo M, Zaw K, Filipova O, Heidarian S, Rafiq N, Julliard K. Multi-drug chemotherapy for pancreatic cancer. Journal of Clinical Oncology 2005, 23 (16S. June 1 Supplement):4267 (abstract).</citation>
  </reference>
  <reference>
    <citation>Bruckner H, Simon K, Hrehorovich V. Low-dose sequential multi-drug regimens for advanced pancreatic cancer. Journal of Clinical Oncology, 2008, 26 (15S, May 20 Supplement) 15568 (Abstract)</citation>
  </reference>
  <reference>
    <citation>Monti DA, Mitchell E, Bazzan AJ, Littman S, Zabrecky G, Yeo CJ, Pillai MV, Newberg AB, Deshmukh S, Levine M. Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7(1):e29794. doi: 10.1371/journal.pone.0029794. Epub 2012 Jan 17.</citation>
    <PMID>22272248</PMID>
  </reference>
  <reference>
    <citation>Goel A, Grossbard ML, Malamud S, Homel P, Dietrich M, Rodriguez T, Mirzoyev T, Kozuch P. Pooled efficacy analysis from a phase I-II study of biweekly irinotecan in combination with gemcitabine, 5-fluorouracil, leucovorin and cisplatin in patients with metastatic pancreatic cancer. Anticancer Drugs. 2007 Mar;18(3):263-71.</citation>
    <PMID>17264757</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2013</study_first_submitted>
  <study_first_submitted_qc>July 22, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 23, 2013</study_first_posted>
  <last_update_submitted>January 17, 2018</last_update_submitted>
  <last_update_submitted_qc>January 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic Cancer</keyword>
  <keyword>G-FLIP, Gemcitabine 5FU Leucovorin Irinotecan Oxaliplatin</keyword>
  <keyword>G-FLIP-DM (G-FLIP + Low doses Docetaxel and Mitomycin C)</keyword>
  <keyword>Vitamin C (ascorbic acid)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Mitomycin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Mitomycins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

